• About Us
  • Kevin Dooley, MD
  • Contact Us
Cure IBM
  • Home
  • IBM FAQ
  • Diagnosis
    • IBM Diagnosis
    • Symptoms
    • Examination
    • Blood Tests
    • Electromyography (EMG) and Nerve Conduction Studies
    • Magnetic Resonance Imaging (MRI)
    • Muscle Biopsy
    • Misdiagnosis
  • Treatment
    • IBM Treatment
    • Medications
    • Clinical Trials
    • Exercise
    • Nutrition and Weight Control
    • Falls
    • Swallowing
    • Psychology
  • Resources
    • Links
    • Glossary
  • IBM Blog
  • Donate
Menu
Ulviprubart in Inclusion Body Myositis—New Results and the Question of Clinically Meaningful Slowing

Ulviprubart in Inclusion Body Myositis—New Results and the Question of Clinically Meaningful Slowing

by Kevin Dooley, MD | Mar 26, 2026 | News and Information

New ENMC Criteria for the Diagnosis of Inclusion Body Myositis

New ENMC Criteria for the Diagnosis of Inclusion Body Myositis

by Kevin Dooley, MD | Apr 18, 2024 | News and Information

Orphazyme Update Regarding Arimoclomol Clinical Trial During Coronavirus Pandemic

Orphazyme Update Regarding Arimoclomol Clinical Trial During Coronavirus Pandemic

by Kevin Dooley, MD | Mar 27, 2020 | News and Information

Arimoclomol Receives FDA Fast Track Designation for Inclusion Body Myositis

Arimoclomol Receives FDA Fast Track Designation for Inclusion Body Myositis

by Kevin Dooley, MD | Dec 18, 2019 | News and Information

Arimoclomol, an investigational drug currently in a Phase 2/3 trial for inclusion body myositis (IBM), has received Fast Track designation from the FDA for treatment of this disabling muscle disease. This designation is designed to shorten the time needed for the FDA...
Regeneron Cancels Clinical Trial of REGN2477 and REGN1033 for Inclusion Body Myositis

Regeneron Cancels Clinical Trial of REGN2477 and REGN1033 for Inclusion Body Myositis

by Kevin Dooley, MD | Mar 27, 2019 | News and Information

Regeneron Pharmaceuticals has confirmed the cancellation of its previously announced Phase 2 clinical trial for inclusion body myositis (IBM). Regeneron had planned to test two therapies in combination to treat this rare muscle disease, which causes gradually...
« Older Entries

Recent Posts

  • Abcuro Raises $66 Million for New Phase 3 Ulviprubart Study in IBM
  • Abcuro to Close Long-Term Extension Study of Ulviprubart in Inclusion Body Myositis
  • Ulviprubart in Inclusion Body Myositis—New Results and the Question of Clinically Meaningful Slowing
  • Pioglitazone in Inclusion Body Myositis: An Early but Encouraging Study
  • Ulviprubart in Inclusion Body Myositis—Phase 2/3 Trial Results

Archives

  • August 2026
  • June 2026
  • March 2026
  • February 2026
  • April 2024
  • August 2023
  • September 2022
  • July 2021
  • March 2021
  • August 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • April 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017

Tags

Abcuro actvin a advocacy arimoclomol atrophy biomarker chloroquine clinical trial clinical trial endpoints clinical trials coronavirus COVAD COVID-19 diagnosis Electrical Impedance Myography falls FDA fundraising hand function helpful devices IBMFRS Inclusion Body Myositis Functional Rating Scale inflammation Living with IBM MDBR Million Dollar Bike Ride mitochondria mri muscle biopsies muscle biopsy muscle degeneration muscle strength myositis clinic myostatin patient story personal story Pioglitazone positive attitude rapamycin research specialty care sporadic inclusion body myositis ulviprubart wheelchairs Yale

Support IBM Research

Join Cure IBM in the fight against Inclusion Body Myositis. Your support will help fund research and the development of treatment options for this debilitating disease.

Donate Today

Subscribe to the Cure IBM Newsletter.

Keep in touch and stay informed by subscribing to our quarterly newsletter.

We will be sending you an email soon. Please open the message and follow the instructions to confirm your subscription.

Subscribe

  • Disclaimer
  • Privacy Policy
  • Terms of Use

© 2026 Cure IBM | Website design and digital media services by Abaton Consulting

  • Follow
  • Follow